Also mentions MYCN:
Maintaining outstanding outcomes using response- and biology-based therapy for intermediate-risk neuroblastoma: A report from the Children’s Oncology Group study ANBL0531.
x hide permanently

MYCN-targeting vaccines and immunotherapeutics.

MYCN-targeting vaccines and immunotherapeutics.

Hum Vaccin Immunother. 2016 Sep;12(9):2257-8

Authors: Schramm A, Lode H

Abstract Amplification and concomitant overexpression of the MYCN oncogene is a frequent event in many malignancies including the childhood tumors, neuroblastoma and medulloblastoma. MYCN is only expressed in a defined time frame during early developmental processes, (1) which is beneficial for approaches combatting tumor-specific MYCN.

Mentions: MYCN